RNA-mediated therapies in myotonic dystrophy-Reference-Cited by-同舟云学术

RNA-mediated therapies in myotonic dystrophy

Published:2018-12 Issue:12 Volume:23 Page:2013-2022
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Overby Sarah J.,Cerro-Herreros Estefanía,Llamusi Beatriz,Artero Ruben

Funder

Fundación Bancaria Caixa d’Estalvis i Pensions de Barcelona, “la Caixa” and Caixa Capital Risc, S.G.E.I.C., S.A

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference68 articles.

1. Myotonic Dystrophy;Harper,2009

2. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member;Brook;Cell,1992

3. Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy;Tsilfidis;Nat. Genet.,1992

4. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons;Jiang;Hum. Mol. Genet.,2004

5. MBNL proteins and their target RNAs, interaction and splicing regulation;Konieczny;Nucleic Acids Res.,2014

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The YBX3 RNA-binding protein posttranscriptionally controls SLC1A5 mRNA in proliferating and differentiating skeletal muscle cells;Journal of Biological Chemistry;2024-02

2. The myotonic dystrophy type 1 drug development pipeline: 2022 edition;Drug Discovery Today;2023-03

3. Automatic Text-Mining Approach to Identify Molecular Target Candidates Associated with Metabolic Processes for Myotonic Dystrophy Type 1;International Journal of Environmental Research and Public Health;2023-01-27

4. Myotonic Dystrophies;Current Clinical Neurology;2023

5. Primary Sjögren's syndrome with type II respiratory failure caused by myotonic dystrophy type 1: A case report and literature review;International Journal of Rheumatic Diseases;2022-12-26